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Endothelial cell-surface tissue 
transglutaminase inhibits 
neutrophil adhesion by binding and 
releasing nitric oxide
Thung-S. Lai1,7, Robert A. Lindberg2, Hua-Lin Zhou5, Zishan A. Haroon3, Mark W. Dewhirst4, 
Alfred Hausladen5, Y.-L. Juang1, Jonathan S. Stamler5,6 & Charles S. Greenberg7
Nitric oxide (NO) produced by endothelial cells in response to cytokines displays anti-inflammatory 
activity by preventing the adherence, migration and activation of neutrophils. The molecular 
mechanism by which NO operates at the blood-endothelium interface to exert anti-inflammatory 
properties is largely unknown. Here we show that on endothelial surfaces, NO is associated with the 
sulfhydryl-rich protein tissue transglutaminase (TG2), thereby endowing the membrane surfaces with 
anti-inflammatory properties. We find that tumor necrosis factor-α-stimulated neutrophil adherence 
is opposed by TG2 molecules that are bound to the endothelial surface. Alkylation of cysteine residues 
in TG2 or inhibition of endothelial NO synthesis renders the surface-bound TG2 inactive, whereas 
specific, high affinity binding of S-nitrosylated TG2 (SNO-TG2) to endothelial surfaces restores the 
anti-inflammatory properties of the endothelium, and reconstitutes the activity of endothelial-derived 
NO. We also show that SNO-TG2 is present in healthy tissues and that it forms on the membranes of 
shear-activated endothelial cells. Thus, the anti-inflammatory mechanism that prevents neutrophils 
from adhering to endothelial cells is identified with TG2 S-nitrosylation at the endothelial cell-blood 
interface.
The physical interaction between neutrophils and activated endothelium is among the earliest events in inflam-
mation1. Initial capture and rolling of neutrophils are primarily mediated by glycoproteins called selectins2. 
E-selectin and P-selectin on the luminal surface of endothelial cells bind to L-selectin on the neutrophil sur-
face2. The firm adhesion of neutrophils to endothelium is then carried out by the leukocyte β2 integrins LFA-1 
and Mac-1 (heterodimeric surface proteins) and their endothelial counter-receptor molecule, intercellular 
adhesion molecule-1 (ICAM-1)3,4. The expression of both neutrophil and endothelial cell adhesion molecules is 
up-regulated by tumor necrosis factor-α (TNFα)5,6.
Nitric oxide (NO) bioactivity can influence both the release of inflammatory cytokines and the expression of 
cell adhesion molecules, and it is recognized that production of NO by endothelial cells regulates neutrophil adhe-
sion in vivo6–11. Endothelium-derived NO that diffuses luminally must avoid inactivation by hemoglobin in the 
blood stream—a problem solved by preserving NO bioactivity in the form of S-nitrosothiols (SNOs), which are 
impervious to heme scavenging12. Under this model, NO bioactivity in endothelium and RBCs may be exchanged 
through sequential transnitrosylation reactions13 involving SNO-proteins spanning the RBC-endothelial cell 
unit12,14. This model is supported strongly by the observation that genetically-induced depletion of RBC SNO 
impairs endothelial relaxations15. In addition, transgenic animals with increased levels of SNOs in red blood cells 
are hypotensive, reflecting connectivity between RBC and vessel wall14,16.
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Tissue transglutaminase (TG2) is ubiquitously distributed17, with the highest expression found in endothelial 
cells (ECs)17,18. TG2 is localized to cell-surfaces (where it is membrane-associated), cytoplasm and nucleus of 
cells17. Through an unconventional mechanism, a considerable amount of TG2 is secreted into the extracellular 
matrix (ECM) and involved in ECM stabilization and cell adhesion17,19,20. TG2 possesses classical transamidation 
activity as well as non-enzymatic activities17,21. The transamidation activity of TG2 is regulated by calcium ions, 
GTP, NO and redox state22,23. TG2 is enzymatically inactive in in the extracellular milleu23, which may be attrib-
uted to its oxidation24. We have previously demonstrated that S-nitrosylation may also inhibit TG2’s activity22. 
S-nitrosylation also regulates TG2 externalization19,20, potentially implicating NO in the mechanism of oxidative 
inactivation. TG2 is S-nitrosylated in young aorta but not in aged aorta25 and deficient S-nitrosylation has been 
linked to vascular stiffness26,27. Extracellular TG2 has also been implicated in Celiac disease, cancer, and fibrotic 
disorders28,29. These in vitro and in vivo data argue for potential roles of non-canonical TG2 activity in human 
health and disease that may be regulated by NO/redox.
TG2 has 18 free sulfhydryl (−SH) groups, several of which are contained within S-nitrosylation motifs22,30, 
consistent with our report that it undergoes poly-S-nitrosylation22. We therefore considered the possi-
bility that TG2 may provide a reservoir of NO bioactivity at the endothelial cell surface. Here we show that 
anti-inflammatory activity of endothelium-derived NO at the endothelial-blood cell interface is conveyed by 
SNO-TG2.
Results
TG2 is bound constitutively to endothelial surfaces at the blood interface and transcriptionally up-regulated by 
TNFα17,31. We sought a model system to examine the effect of surface-bound TG2 on polymorphic neutrophil 
(PMN) adherence and to test the influence of NO under inflammatory condition. Confluent HUVEC cells were 
treated with increasing concentrations of TNFα and and the expression of various cell adhesion molecules were 
investigated. After 5 hours of TNFα treatment, cells remains viable as examined by morphology and cell viabil-
ity assays (Supplemental Fig. 1). The expression of cell adhesion molecules including E-selectin, ICAM-1, and 
P-selectin were found to be upregulated by TNFα treatment (Supplemental Fig. 2). By contrast, TNFα did not 
alter the surface expression of TG2, which was found to be constitutively expressed on the luminal surface of 
HUVECs monolayers (Supplemental Table 1).
To directly visualize surface-bound TG2, we added glutathione S-transferase (GST)-TG2 (or active site mutant 
GST-TG2/C277A) to confluent HUVEC monolayers. Isolation of total cytosolic and membrane fractions con-
firmed that both GST-TG2 and GST-C277A/TG2 were bound to the surface of endothelial cells (Supplemental 
Figs 3 and 4). GST-TG2/C277A binding increased following TNFα treatment of HUVECs. GST-TG2-treated 
samples showed multiple high molecular weight bands, likely reflecting crosslinking by canonical TG2 activ-
ity (Supplemental Fig. 3). Endogenous TG2 (80 kDa) is predictably distributed between cytosol and membrane 
(Supplemental Figs 3 and 4).
Additional experiments were carried out to validate the surface localization of TG2. TG2 was found to express 
on HUVEC surfaces using non-permeabilized cell staining and fluorescent visualization (Fig. 1). Cell surface 
biotinylation (labeled with a cell-impermeant Biotin-XX sulfosuccinimidyl ester) followed by streptavidin 
pull-down also demonstrated labeling of endogenous and exogenous TG2 (Fig. 2).
Figure 1. Immunofluorescent staining of TG2 in TNFα-treated HUVEC cells. HUVEC cells were grown 
and treated with or without TNFα (10 ng/ml) for 5 hours. The cells were non-permeabilized, fixed with 4% 
paraformaldehyde and stained with mouse monoclonal anti-TG2 (TG100) followed by donkey anti-mouse 
IgG (Fitc conjugated, shown in Green). The fluorescent signal was visualized using fluorescent microscopy. The 
nuclei were stained with Hoesche 33342 (shown in blue).
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We determined that specific TG2 binding sites could be saturated by the addition of TG2. Using an ELISA 
assay to measure surface-bound TG2, the addition of 50 nM TG2/C277A resulted in a two-fold increase in surface 
binding (mean relative OD405 nm = 0.053 ± 0.028 vs. 0.105 ± 0.017; n = 4, p < 0.05) (Supplemental Table 1). The 
binding of TG2/C277A did not alter either the constitutive or TNFα-induced expression of ICAM-1 as measured 
by flow cytometry (Supplemental Fig. 5).
As extracellular TG2 is enzymatically inactive23, we employed the enzymatically- inactive mutant, TG2/
C277A, to examine the role of TG2 on PMN binding to endothelium. Recombinant TG2/C277A was added to 
HUVEC monolayers after the activation with TNFα, and PMN adherence was then monitored under physiologi-
cal shear (to simulating blood flow). TG2/C277A inhibited both the initial binding and the attachment (>30 sec) 
of PMNs (Fig. 3) with complete inhibition of binding seen at 100 nM TG2/C277A (Supplemental Fig. 6), and inhi-
bition was maintained across the physiological range of shear rates (τω = 0.4–20 dyn/cm2; p < 0.05) (Fig. 3). There 
was no difference in neutrophil rolling in the presence or absence of TG2/C277A (PMN roller flux = 16 ± 8.5 vs. 
19 ± 7.8 at τω = 1 dyn/cm2, respectively. n = 3; p < 0.05), indicating that the inhibition of neutrophil adhesion 
was due to an effect on PMN attachment (data not shown). Interestingly, active TG2 was found to have less 
anti-adhesive effects than the mutant (Supplemental Fig. 7). Thus, the activity of extracellular TG2 reduces its 
anti-PMN binding ability, and TG2/C277A binding to TNFα activated endothelial cells inhibits PMN binding, 
independent of TG2’s transamidation activity.
We have shown previously that stimulation of endothelial nitric oxide synthase (eNOS) within aortic endothe-
lial cells (by treatment with Ca2+ ionophore) results in the S-nitrosylation of exogenous TG222. Similarly, follow-
ing addition of TG2/C277A to HUVECs, activation of eNOS by shear stress resulted in the S-nitrosylation of 
about 14% of exogenous TG2/C277A thiols (comparable to results with aortic endothelial cells18). In our current 
work, shear stress activation of eNOS led to a large decrease in the adherence of PMNs, and this effect was abro-
gated by treatment with the NOS inhibitor L-NMMA, whereas addition of S-nitrosylated TG2/C277A inhibited 
PMN adherence in the presence of L-NMMA (Fig. 4). Further, pre-treatment of TG2/C277A with the thiol alkyl-
ating agent iodoacetamide, which would prevent subsequent S-nitrosylation, abrogated the decrease in adherence 
consequent upon activation of eNOS (Fig. 4). Thus, the ability of TG2 to inhibit PMN adherence to endothelial 
cells may be dependent upon S-nitrosylation of TG2, and the active site (C277) of TG2 is not involved.
Finally, we determined that SNO-TG2 is present in vivo, as demonstrated following resin-assisted cap-
ture (SNO-RAC) of SNO-TG2 from three different mouse kidney extracts (Fig. 5). Scanning densitometry of 
SNO-TG2 demonstrates that almost 50% (44 ± 15%) of TG2 is S-nitrosylated in situ (Fig. 5). As a further control, 
we show that GAPDH, a prototypic SNO-protein32, is readily detected under these conditions.
Discussion
Endothelial NO synthase is localized to the plasma membrane to enable NO production at cell-cell interfaces. 
In conventional models, NO diffuses luminally to exert anti-inflammatory activity by preventing neutrophil 
adhesion. Accumulating evidence indicates, however, that NO bioactivity in vivo, including anti-inflammatory 
Figure 2. Cell surface biotinylation of cell surface proteins identifies endogenous and exogenous TG2. HUVEC 
confluent monolayers were incubated with GST-TG2/C277A (50 nM) during the last hour of a 5 hr TNFα 
(10 ng/ml) treatment. Total cell lysates including membrane fractions were isolated after cell surface proteins 
biotinylation as described under Materials and Methods. (A) Total cell lysates (15 μg) were separated by SDS-
PAGE and transferred to PVDF membrane. Blots were developed using Streptavidin-HRP and bands were 
visualized using ECL chemiluminescence as described under Materials and Methods. (B) Streptavidin bead 
pull-down of biotinylated proteins from total cell lysates derived from (A) were performed as described under 
Materials and Methods. The bound biotinylated proteins were eluted from streptavidin-beads by incubating 
with SDS-PAGE loading buffer with heating at 95 °C for 4-min. Half of the eluted samples were loaded on 
a SDS-PAGE and transferred to PVDF membrane. Blots were developed using TG2 mouse monoclonal 
antibody (cub7402) and goat vs mouse IgG conjugated with HRP and bands were visualized using ECL 
chemiluminescence.
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activity, is conveyed mainly through SNOs, which entails S-nitrosylation of key target proteins33–35. Under this 
model, NO bioactivity in the endothelium would transfer to blood cells through coupled equilibria involving 
SNOs13. Endothelial cell surfaces (and adjacent ECM) are in fact rich in protein thiols, raising the idea that SNOs 
at the cell surface may provide a source of NO bioactivity. Here we show that SNO-TG2 is readily detectable in 
highly vascularized tissues (Fig. 5). We also show that TG2 serves as a co-factor for endothelium relaxing factor 
(EDRF)/NO bioactivity, specifically, in maintenance of a non-adherent endothelial surface.
Figure 3. TG2/C277A inhibits neutrophil adhesion to TNFα-activated endothelium. HUVEC monolayers 
were treated with TG2/C277A (10 nM) during the last hour of a 5 hr TNFα (10 ng/ml) treatment. After infusion 
of neutrophils (PMN), cultures were exposed to shear stress at the values indicated, and adherent PMNs were 
then counted. Data are presented as means ± SEM. TNFα, n = 5; TNFα/TG2/C277A, n = 4. p < 0.05, TNFα 
vs. TNFα/TG2/C277A at all shear stress values. The statistical significance at each shear stress was analyzed 
using student t-tests. Asterisks denote significant differences. The p-values at each shear stress are as followings: 
0.5 dyn/cm2, p = 0.023902; 1 dyn/cm2, p = 0.010764; 2.0 dyn/cm2, p = 0.007297; 4.0 dyn/cm2, p = 0.008728; 
8.0 dyn/cm2, p = 0.015503; 20 dyn/cm2, p = 0.010764.
Figure 4. Inhibition of PMN adhesion to endothelial cells is NO dependent. Inhibition of NO synthase (NOS) 
with L-NMMA prevents inhibition by TG2/C277A of PMN adhesion to endothelial cells pretreated with TNFα, 
and exogenously S-nitrosylated TG2/C277A inhibits PMN adhesion to TNFα-activated PMNs in the presence 
of L-NMMA (150 μM). Alkylated TG2/C277A (iodo-TG2/C277A) also prevents inhibition of PMN adhesion. 
TNF-activated endothelial cells were treated with TG2/C277A, iodo-TG2/C277A or S-nitrosylated TG2/C277A 
(50 nM, 1 hr) and exposed to flow for 20 min prior to infusion of PMNs. Wall shear stress (τω) = 1 dyn/cm2. 
Data are presented as means ± SEM, n ≥ 3. *p < 0.05 vs. TNFα. Statistical analysis was performed with a single-
factor ANOVA using shear stress = 1.0 dyn/cm2 in all groups: TNFα vs. TNFα/C277A/TG2 (p = 0.002); TNFα/
TG277A vs. TNFα/L-NMMA/C277A/TG2 (not nitrosylated) (p = 0.003); TNFα/L-NMMA/SNO-C277A/TG2 
vs. TNFα/L-NMMA/C277A/TG2 (not nitrosylated) (p = 0.00044).
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Endothelial cells are among richest cellular sources of TG218. TG2 is concentrated in or at the cytoplasm, 
nucleus and plasma membrane where it contributes reducing equivalents (18 SH groups per protein)17. TG2 is 
also secreted on to endothelial surfaces, where it functions as a co-receptor for fibronectin36, and into the ECM 
(where it also binds fibronectin). TG2 is therefore a potential candidate for modulation of a variety of endothelial 
cell functions. Here we describe a novel and unanticipated role for TG2 in transducing the anti-adhesive proper-
ties of cytokine-activated endothelial cells.
Extracellular TG2 is oxidatively inactivated in vivo and does not mediate transamidation reactions23. Therefore 
to mimic physiological conditions, we used an active site mutant, TG2/277A23. Because TG2/C277A is devoid 
of enzymatic activity, it cannot alter cell adhesion forces directly. Using non-permeabilization fixation stain-
ing and cell surface biotinylation techniques, we confirmed that TG2 is expressed on the surface of control and 
TNFα–stimulated cells (Figs 1 and 2), and that surface-bound C277A/TG2 (Supplemental Figs 3 and 4) retains 
ability to inhibit neutrophil adhesion. We further showed that the anti-adhesive properties of TG2 are dependent 
on both cysteine thiols and NO. In particular, inhibition of eNOS prevented the inhibition by TG2 of neutrophil 
adhesion to TNFα-activated endothelial cells. We also showed that S-nitrosylated TG2/277A recapitulated the 
anti-inflammatory property of endothelial surfaces. It has been previously reported that TG2 S-nitrosylation, 
protects against vascular stiffness25. However, this function is critically dependent on the enzymatic activity of 
intracellular TG2. Thus, S-nitrosylated TG2 is formed both intracellularly and extracellularly to regulate vascular 
stiffness and inflammation, respectively.
The regulation of extracellular TG2’s enzymatic activity has been the subject of intense interest since TG2 is 
involved in the pathogenesis of a number of inflammatory disorders, including arteriosclerosis25, fibrosis and 
Celiac disease21,29. In Celiac disease, TG2’s enzymatic activity is responsible for the deamidation of gluten pep-
tides, which trigger an inflammatory T cell response, ultimately resulting in the destruction of the small-bowel 
mucosal architecture37. Circulating IgA in the blood of Celiac patients collaborates with thioredoxin to activate 
extracellular TG224,38. By contrast, in our model of vascular inflammation, the activity of extracellular TG2 was 
dependent on its S-nitrosylation state and inactivation by NO was associated with enhanced anti-inflammatory 
properties.
The current paradigm regarding leukocyte-endothelium interactions indicates that initial capture and rolling 
of leukocytes is mostly mediated by low affinity selectins39, whereas firm adhesions are mediated by ICAM-1 
and integrins. Initial low affinity interactions are subsequently strengthened as a result of leukocyte activation. 
In our leukocyte adhesion model, E-selectin, P-selectin and ICAM-1 are all induced after TNFα treatment (see 
Supplemental Fig. 2). However, cell surface C277A/TG2 did not affect leukocyte rolling. Inhibition by SNO-TG2 
of firm adhesion would be consistent with the known effect of endothelial NO to inhibit ICAM-1 expression40. 
Further studies are needed to elucidate the exact mechanism by which SNO-TG2 inhibits leukocyte adhesion.
Our findings demonstrate a role for TG2 in transducing the anti-inflammatory properties of NO produced 
by shear- and cytokine-activated endothelial cells and show that NO bioactivity identified with eNOS is, at least 
partly, juxta-membrane SNO-TG2. Thus, it would appear that endothelial NO does not diffuse into the lumen to 
inhibit neutrophils, but rather concentrates on the luminal surface to prevent neutrophil attachment. These data 
expand the perspective on the co-localization of NO sources and targets to include endothelial NOS and extracel-
lular surface ligands41, and emphasize that NO bioactivity may derive from sources other than NOS. Inasmuch as 
the anti-adhesive properties of NO are mediated by S-nitrosylation of neutrophil proteins (e.g. NFκB), delivery 
of NO bioactivity by SNO-TG2 may occur via sequential transnitrosylation reactions, by analogy to the coupled 
equilibria between SNOs in RBCs and the vascular wall that dispense NO bioactivity12,13.
Figure 5. Endogenous TG2 is robustly S-nitrosylated in Mouse Tissues. SNO-TG2 isolated from three separate 
mouse kidneys (designated as 1, 2 and 3). 10 μg samples were loaded on to each lane for immunoblot analysis. 
(A) 0.5% of total input (B). Proteins eluted from ascorbate treated samples (+ascorbate) = SNO-proteins. 
(C). Proteins eluted from untreated samples (−ascorbate) = controls. SNO-modified TG2 was eluted from 
thiopropyl-Sepharose beads and analyzed by immunoblots using mouse monoclonal antibody against TG2 
(cub7402, ThermoFisher Scientific) as described under Materials and Methods. GAPDH, a prototypic SNO-
modified protein (detected using rabbit monoclonal antibody Abcam, Ab181602) is included as a control.
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We showed previously that activating eNOS within endothelial cells by increasing intracellular Ca2+ levels 
with Ca2+ ionophore leads to S-nitrosylation of TG2 and here extend our finding to shear stress, which similarly 
activates eNOS by increasing intracellular Ca2+ levels. We have also shown that Ca2+ can effect NO group release 
from SNO-TG2 by an allosteric mechanism22, and it has also been reported that S-nitrosylation of TG2 may reg-
ulate its distribution between intracellular and extracellular loci20. Thus, our data raise the intriguing possibility 
that regulation of NO bioactivity at the endothelial-blood interface may depend on whether Ca2+ originates from 
extracellular or intracellular pools: whereas intracellular Ca2+ will activate eNOS to S-nitrosylate TG242, Ca2+ 
released extracellularly (e.g. by adhering neutrophils) might release NO groups from surface TG2. SNO-TG2 may 
also serve to prevent adherence of platelets and RBCs, emphasizing that SNOs within membranes have additional 
signaling functions43.
Externalization of TG2 by aortic endothelial cells (and by inference amounts of surface bound SNO-TG2) 
was decreased by high levels of sustained laminar shear stress (18 dynes/cm2 for 16 hr)19. By contrast, brief peri-
ods of laminar shear stress (<1 min under each shear stress range from 0.4 to 20 dynes/cm2) lead to robust 
S-nitrosylation of externalized TG2. TG2 localization, activity and function are thus predicted to vary in vascular 
health and disease and to reflect the S-nitrosylation state at the cell-cell interface.
Experimental procedures
Reagents. Reagents and materials were obtained from the following suppliers: Medium 199 (M-199, Earle’s 
salts or Hank’s salts), antibiotic/antimycotic (pen-strep-amphotericin), L-glutamine, heparin (sodium salt), and 
trypsin (0.05%) (Gibco/Life Technologies, Grand Island, NY); fetal bovine serum (HyClone, Orem, Utah); col-
lagenase type I (Worthington Biochemical Corp., Freehold, NJ); endothelial cell growth supplement (ECGS), 
human recombinant TNFα, FITC-goat anti-mouse IgG, p-nitrophenyl phosphate (PNPP) (Sigma, St. Louis, 
MO); DiI-labeled acetylated-low density lipoprotein (DiI-Ac-LDL; Biomedical Technologies, Inc., Stoughton, 
MA); lymphocyte separation medium (Organon Teknika, Durham, NC); anti-ICAM-1 monoclonal antibody 
(clone LB-2; Becton Dickinson, San Jose, CA); anti-transglutaminase II monoclonal antibody (clone CUB7402; 
Labvision/Thermo Scientific, Fremont, CA); mouse IgG (Jackson Immunoresearch, West Grove, PA); Background 
Buster and Immunodiluent (Innovex Biosciences, Richmond, CA); goat anti-mouse IgG-alkaline phosphatase 
(GAM-AP; BioRad, Hercules, CA).
Cells. Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical cords using standard 
methods44 or purchased from Lonza (Atlanta, GA). For flow chamber studies, flow cytometry, or binding exper-
iments, HUVEC (passage 2–4) were cultured on 1% gelatin-coated sterile glass slides, 6-well or 96-well culture 
plates, respectively, until confluent. Human neutrophils were isolated from the citrate-anti-coagulated periph-
eral blood of healthy volunteers following the sedimentation and hypotonic lysis of erythrocytes10, and were 
re-suspended at 0.5 × 106 cells/ml in M-199 (37 °C) 20 min prior to flow chamber infusion.
Human subjects. All experiments performed in this study were approved and in accordance with guidelines 
and regulations as defined by Duke’s Institutional Review Board. For neutrophil isolation, blood was collected 
from healthy human volunteers via venipuncture after informed consent. Informed consent was obtained from 
all subjects. After obtaining IRB approval, the umbilical cords that are normally discarded after healthy vaginal 
deliveries of newborns provided the source for the HUVEC.
Expression/purification of TG2 and active site mutant. Purification of wild-type TG2 and active site mutant 
(TG2/C277A) proteins, the conditions for growing Escherichia coli harboring either the TG2 or TG2/C277A 
vectors, and the purification of glutathione-S-transferase (GST) fusion proteins were as previously described45. 
Except as mentioned in the text, GST was cleaved from the purified GST-TG2/C277A fusion protein (called 
C277A) by incubating with factor Xa (1% w/w, Hematologic Technologies, Inc.) overnight at 4 °C and reapplied 
to the glutathione resin to remove the cleaved GST protein. Protein concentrations were determined using the 
Bradford method.
Iodoacetamide treatment of TG2 (IODO-TG2). Recombinant GST-TG2/C277A (1 µM) was incubated with 
10 µM of freshly prepared iodoacetamide in buffer containing 50 mM Tris-Cl, pH 7.5, 100 mM NaCl, and 1 mM 
Ca2+ at room temperature for 30 min. After incubation, excess iodoacetamide was removed by dialysis in 4 × 1 
liter of buffer containing 50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 10% glycerol for 24 hours.
Cell treatments. Confluent monolayers of HUVEC were treated with TNFα (10 ng/ml in serum-containing 
media) for 5 hr prior to experimentation, and during the final hr treated with different concentrations of TG2/
C277A in M-199 (3.7 mM Ca2+, no serum).
Flow chamber. Glass microscope slides with confluent HUVEC monolayers were incorporated into a par-
allel plate flow chamber. The two halves of the chamber were separated by a 0.005 silicone gasket (Specialty 
Manufacturing, Inc., Saginaw, MI), which defined the flow path across the endothelial monolayer. Flow medium 
(M-199 with Hank’s salts, pH 7.4, 37 °C) was pumped through the chamber (#600-000; Harvard Apparatus, Dover, 
MA) to generate a shear stress (τα) = 0.4 dyn/cm2 across the monolayer, which is within the physiologic range 
estimated in post-capillary venules46 and tumor microvessels47. The flow chamber was mounted on the stage of 
an inverted microscope (Zeiss Televal 31, Carl Zeiss, Inc., Thornwood, NY) and the monolayer was visualized 
via a 10× phase contrast objective (32× overall magnification) and a closed circuit videomicroscopy system, 
consisting of a Newvicon C2400 tube camera (Hamamatsu Photonics, Hamamatsu, Japan), videotimer (VTG-33; 
FOR.A, Tokyo, Japan), videotape recorder (SVO-9500MD; Sony, Tokyo, Japan) and monitor (CVM-131, Sony). 
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Following 20 min of preconditioning HUVECs to flow, neutrophils were infused for 5 min, at which time video-
taping of an 800 µm × 800 µm area of the monolayer was begun. At 30 sec intervals, the flow rate was increased in 
stepwise fashion, such that τα = 0.4, 1, 2, and 4 dyn/cm2. The range of flow rates used corresponds to Reynolds 
numbers = 1.5–15.4, indicating the presence of fully developed laminar fluid flow within the flow path. The den-
sity of adherent neutrophils was defined as the number of neutrophils remaining stationary (i.e, movement <1 
cell diameter within 30 sec) per mm2 for a given τα. Adherent neutrophils were initially identified at τα = 0.4; 
subsequently only these adherent neutrophils were followed at higher shear rates. The flux of rolling neutrophils 
was defined as the number of neutrophils per 30 sec displaying transient interactions with the monolayer past an 
arbitrarily defined line (200 µm) orthogonal to axis of flow, for postcapillary venular shear stresses (τα = 0.4 or 
1 dyn/cm2 only).
Shear activation of endothelial cells. HUVEC cells (passage 2–3, Hyclone Laboratories) were grown to conflu-
ence on microcarrier beads. TG2/C277A (1 μM) was then added in a final volume of 200 μl and incubated at room 
temperature for 10 min in a glass cylinder (1 cm in diameter, containing ~3 × 107 cells total) designed to generate 
rotational shear stress as previously described22,48. Recombinant TG2/C277A was recovered from the mixture by 
low speed centrifugation. Supernatants were store at −80 °C for SNO content determination (Nitrolite and TEA 
model 543 Analyzer, Thermedics, Woburn, MA) as described22.
ICAM-1 expression by flow cytometry. HUVECs that had been treated with TNFα and/or TG2/C277A were 
trypsinized, washed, re-suspended in M-199, and prepared for immunofluorescent staining as previously 
described49. HUVEC were washed (2% BSA, 0.1% NaN3 in PBS) without permeabilization, and incubated with 
either anti-ICAM-1 or mouse IgG (4 °C, 30 min). Following several washes, cells were incubated with FITC-goat 
anti-mouse IgG (4 °C, 30 min), washed, and fixed (1% paraformaldehyde) for later flow cytometric analysis 
(Comprehensive Cancer Center Flow Cytometry Lab, Duke University Medical Center).
TG2/C277A binding assay. HUVEC were seeded into 96-well plates at 25,000 cells/well, cultured overnight, 
and then treated with 10 ng/ml TNFα for 5 hrs (37 °C), with 50 nM TG2/C277A added to specified wells. Wells 
were then washed x3 with HBSS, fixed with 80% methanol (10 min at room temp [RT]), rinsed and incubated 
with a blocking solution (Background Buster; 10 min, RT). Wells were then incubated with either PBS, mouse 
IgG, or a TG2 monoclonal antibody (clone CUB7402, 200 µg/ml stock, 1:50 dilution, 30 min, RT) diluted in 
Immunodiluent. Monolayers were rinsed ×3, incubated with goat anti-mouse-alkaline phosphatase (30 min, RT), 
and rinsed again. The signal was developed with PNPP and OD readings were determined with a kinetic micr-
otiter plate reader (30 min, RT, 30 sec intervals, 405 nm) (ThermoMax Microplate Reader, Molecular Devices) 
controlled by SoftMax software.
S-Nitrosylation of TG2/C277A in vitro. S-nitroso-TG2/C277A (SNO-TG2/C277A) was prepared by incubat-
ing TG2/C277A with excess S-nitrosocysteine (in 0.1 mM Tris-acetate, pH 7.5 and 0.1 mM EDTA) at room 
temperature for 10 min22. After S-nitrosylation, free S-nitrosocysteine was removed by dialyzing against 4 × 1 
liter of buffer containing 50 mM Tris-acetate, pH 7.5, 100 mM NaCl, 10% glycerol at 4 °C22,50. SNO content was 
determined with a photolysis/chemiluminescence detection system (Nitrolite and TEA model 543 Analyzer, 
Thermedics, Woburn, MA) as described22.
Immunofluorescent staining. Monolayers of HUVEC were treated with TNFα (10 ng/ml in serum-containing 
media) for 5 hr prior to staining. Cells were immediately fixed with 4% paraformaldehyde to make membrane 
non-permeabilize followed by blocking with BSA. TG2 was first incubated with monoclonal antibody against 
TG2 (TG100) (Labvision, Thermofisher), followed by Donkey anti-mouse IgG conjugated with FITC (Jackson 
immuno-research) and nuclei was stained with Hoesche 33342.
Cell surface protein biotinylation. To label surface expression of endogenous TG2 and exogenous GST-C277A/
TG2, HUVEC cells were treated with TNFα for 5 hours and 50 nM of GST-C277A/TG2 cells was added 
at the final hour. Cell surface proteins were labeled using FluoReporter™ Cell-Surface Biotinylation Kit 
(ThermoFisher Scientific) on ice according to the instruction manual. Briefly, Biotin-XX sulfosuccinimidyl 
ester (a cell-impermeant, amine reactive compound) was the active compound that labeled cell surface proteins. 
After three washes with PBS, cells were lysed with 10 mM HEPES, pH 8, 2 mM EDTA, and 0.5% NP40, protease 
inhibitors. Total cytoplasmic and membrane fractions were isolated using low speed (500 × G) centrifugation. 
Biotinylated proteins were isolated on Streptavidin-Dynabead (ThermoFisher Scientific) and analyzed.
Resin Assisted Capture for TG2 S-nitrothiols (SNO-RAC). The analysis of SNO-modified TG2 was carried out 
with the SNO-RAC method essentially as described51. Briefly, C57/B6 mice kidneys were homogenized in lysis 
buffer (1 g/5 ml lysis buffer) containing 100 mM Hepes/1 mM EDTA/1 mM DTPA/100 mM neocuproine (HEN), 
0.1% (vol/vol) Nonidet P-40, a thiol-blocking agent, 0.2% S-methylmethanethiosulfonate (MMTS), and protease 
inhibitors (Roche). After centrifugation 2X at 20,000 × G for 20 min at 4 °C, SDS was added to the supernatants 
to 2.5% and incubated at 50 °C for 20 min. Proteins were precipitated with −20 °C acetone, and re-dissolved in 
1 mL of HEN/1% SDS. Precipitation of proteins were repeated with −20 °C acetone, and the final pellets were 
resuspended in HEN/1% SDS and protein concentrations determined using Bicinchoninic Acid (BCA) method. 
Total lysates (2 mg) were incubated with freshly prepared 50 mM ascorbate/thiopropyl-Sepharose and rotated 
end-over-end in the dark for 4 h. The bound SNO proteins were sequentially washed with HEN/1% SDS and 0.1X 
HEN/0.1% SDS, SNO proteins were eluted with 0.1 × HEN/1% SDS/10% β-meracaptoethanol and analyzed by 
SDS/PAGE and Immunoblotting blotting.
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Statistical analysis. Comparisons of mean adherent neutrophil density, roller flux, and TG2/C277A-HUVEC 
binding were tested for differences within each shear stress using Student’s (unpaired) t-tests (p < 0.05). GraphPad 
Prism software was used to analyze the data using a single-factor ANOVA. In addition, posthoc testing using 
Sidak’s multiple comparisons test to identify the source of statistically significant difference.
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